BIO 2012: Development cost comparison, China vs. US

BIO 2012: Development cost comparison, China vs. US

I attended BIO this year, and while there I felt responsible for China as a Trade Secrets contributor, so I settled in at “The China Day” – a day-long program organized around China, and was happy to take down some interesting numbers from the morning session.  Read more

Demystifying China: Understanding the Chinese IND approval process

Demystifying China: Understanding the Chinese IND approval process

Last year, several inquiries to us at Modular R&D, where I am a managing partner, were from companies new to China, on the subject of filing clinical trial applications. We hear comments such as “It’s taking too long,” “I cannot give out this information,” and “Why do I need to do an expensive long-tox study for a phase II?”  These are usually expressed in great frustration. So we did a workshop recently at the ChinaTrials conference, and worked with experts in regulatory affairs and preclinical studies from US, Europe and China, to look at the Chinese IND process in detail, especially how it compares to the US investigational new drug (IND) application and EU Clinical Trial Application (CTA).  Read more

Demystifying China: Funding sources for startups

Demystifying China: Funding sources for startups

During lunch the other day, Walter Lau and I tackled a question raised by a Trade Secrets reader: “How can a small biotech raise funding in China, after having biological proof of concept?” Walter is a managing partner of Cenova Ventures, one of the few healthcare-focused VC funds in China. The question really needs to be answered in two parts: one for the Chinese biotech companies, the other for international biotech companies hoping to get funding in China. For typical Chinese biotech companies, the first and main source is most often the government. The funding comes from national as well  … Read more

Demystifying China: Start up

Demystifying China: Start up

People read a lot about China these days. There is the booming economy, maintaining over 8% GDP growth in the midst of a slow global recovery. The Chinese pharmaceutical market is projected to climb into the world’s top three in 2011. The healthcare reform plan is supposed to inject US$128 billion into the healthcare system between 2009 and 2011, and has already helped double pharmaceutical sales one and a half years into the plan. We also hear trendy phrases such as the globalization of drug development, the new paradigm of drug development, FIPnet (Fully Integrated Pharmaceutical Network), superpharma, virtual biotech…and  … Read more